Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arxxant’s Fate In Question After FDA Requests Additional Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly may seek a development partner for the diabetic retinopathy treatment to collect the three additional years of efficacy data sought by FDA.

You may also be interested in...



Future Of Lilly’s Arxxant In Doubt

Lilly says it is considering options for the investigational diabetic retinopathy treatment after FDA rejected the company's appeal of a recent "approvable" decision.

Future Of Lilly’s Arxxant In Doubt

Lilly says it is considering options for the investigational diabetic retinopathy treatment after FDA rejected the company's appeal of a recent "approvable" decision.

Lilly Licenses OSI Glucokinase Activator Program For Type 2 Diabetes

The nearly $400 million deal gives Lilly exclusive rights to OSI’s GKA drugs, including a lead compound in Phase I studies.

Related Content

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel